Healthcare: Earnings Round-up -- Celgene and Gilead Sciences

<p>How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.</p> <p> </p>